Two studies provide insights into the biological basis of triple-negative breast cancer
Potential novel drivers of chromosome instability and biomarkers of early recurrence were identified
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
AI-driven multimodal strategy improves risk stratification in early breast cancer
Integrating digital pathology with genomic and clinical data may enhance prediction of late recurrence and refine selection for adjuvant treatment intensification in HR-positive, HER2-negative disease
Sustained quality-of-life benefits reported with first-line antibody-drug conjugate in triple negative breast cancer
Patient-reported outcomes show that datopotamab deruxtecan also improved patient functioning and symptom control compared to chemotherapy
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
Can digital tools improve personalised support for adolescents and young adults with cancer?
Gaps still exist in care and communication for AYA, with failure to address their unique needs
The role of ctDNA surveillance is still uncertain in early breast cancer
Data from two novel studies further support the feasibility of this approach, although its clinical utility has yet to be determined
Chemotherapy-free adjuvant treatment preserves quality of life in HER2-positive early breast cancer
A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting